MCM
BCLI

Monument Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Monument Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22
Closed -$1K – 116
2018
Q3 		$1K Hold
22
– – ﹤0.01% 261
2018
Q2 		$1K Hold
22
– – ﹤0.01% 142
2018
Q1 		$1K Hold
22
– – ﹤0.01% 132
2017
Q4 		$1K Buy
+22
New +$1.32K ﹤0.01% 117

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CPP
Crow Point Partners Boston, Massachusetts $64M AUM 33.5% 1-Year Est. Return

Monument Capital Management's BCLI Position: Q4 2018 in Review

Monument Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2018, closing a stake of 22 shares — an estimated $1K sold.

Monument Capital Management first reported a position in BCLI in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 36 funds tracked by Wall St. Rank hold BCLI as of Q4 2018.

  • Monument Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2018 after selling out during the quarter.
  • Monument Capital Management sold 22 BRAINSTORM CELL THERAPUTC shares in Q4 2018, an estimated $1K.
  • Monument Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2017 and held it in 4 quarters.
  • Monument Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $1K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2018.

Based on Monument Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.